Dassault in talks to buy ArisGlobal from Nordic Capital for ~$2B

Dassault Systèmes, better known for the software that Airbus, Boeing and the big automakers use to design planes and cars, is reportedly circling one of the less glamorous corners of pharma software. According to the Financial Times, the French group is in talks to buy ArisGlobal, a drug-trial software maker, from Nordic Capital for about $2 billion.

The interesting thing is not the price tag on its own, it is the shape of the portfolio Dassault is quietly assembling. The company already owns Medidata, which it bought in 2019 for $5.8 billion and which sits at the heart of clinical-trial execution for a large share of the industry. ArisGlobal's software runs the parts around that: regulatory submissions, drug-safety and pharmacovigilance case management, the post-market work that happens after a molecule is approved. Bolting one onto the other would give Dassault something close to an end-to-end life-sciences stack, at a moment when the company is, as Reuters put it via Euronext, "increasingly tapping augmented AI and data centers to drive growth" while its industrial customers absorb an automotive slowdown. First-quarter 2026 revenue came in at 1.51 billion euros, so a ~$2B check is meaningful but not company-defining.

Why it matters for the rest of the field: the buyers of this software are the same twenty or so big pharma companies. If one vendor can credibly say it covers trial design, execution and safety in one contract, procurement gets simpler and switching costs get stickier. Veeva, Oracle, IQVIA and Clario would suddenly be competing against a single incumbent rather than picking off point solutions.

The honest caveat is that the reporting is single-sourced and tentative. The FT itself flags that a transaction is "not a foregone conclusion" and that talks could still fall apart, and neither Dassault nor Nordic Capital had commented at the time of writing. What the reporting does not give you is the multiple, the financing mix, the retention terms for ArisGlobal's leadership, or which regulators would need to bless a combination of this size in clinical-trial software.

If the deal does close, the operators worth watching are not at Dassault, they are at every rival pitching a piece of the pharma software stack. That is where the next twelve months of positioning gets decided.